CLN Insider Trading Activity and SEC Form 4 Filings
CLN insider trading summary
No open-market insider purchases or sales of Celsion CORP (CLN) have been reported on SEC Form 4 in the past 12 months.
Latest CLN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 18, 2008 | Nicholas Borys | VP & Chief Medical Officer | Buy | $12K (3,000 @ $4.10) |
| Feb 26, 2008 | Gary W Pace | Director | Buy | $25K (4,000 @ $6.27) |
| Feb 25, 2008 | Gary W Pace | Director | Buy | $12K (2,000 @ $6.17) |
| May 18, 2007 | Max Link | Director | Buy | $48K (10,000 @ $4.84) |
| May 17, 2007 | Michael H Tardugno | President, CEO | Buy | $3K (600 @ $4.82) |
| May 17, 2007 | Michael H Tardugno | President, CEO | Buy | $9K (1,784 @ $4.81) |
| Feb 27, 2007 | Max Link | Director | Buy | $35K (10,000 @ $3.49) |
| Feb 26, 2007 | Max Link | Director | Buy | $35K (10,000 @ $3.50) |
| Feb 23, 2007 | Michael H Tardugno | President, CEO | Buy | $26K (7,616 @ $3.46) |
| Feb 23, 2007 | William Hahne | VP of Research & Development | Buy | $21K (6,000 @ $3.55) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.